Synairgen (SNG)

 

Latest News

Synairgen revises collaboration with Pharmaxis

Synairgen, the respiratory drug discovery and development company, has revised its collaboration agreement with Pharm...

Update on LOXL2 Programme&Pharmaxis Collaboration

RNS Number: 3339Z Synairgen plc 14 December 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Update on LOXL2 Programme and Collaboration with Pharmaxis 5M payment to Synairgen plus percentage of all future partnering revenues Southampton, UK - 14 December 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development co...

Holding(s) in Company

RNS Number: 9658V Synairgen plc 08 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Synairgen Plc 1b. Ple...

Interim results for six months ended 30 June 2017

RNS Number: 8967R Synairgen plc 27 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2017 Southampton, UK - 27 September 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 J...

All News

DateHeadlineSource
14-12-17Synairgen revises collaboration with PharmaxisStockMarketWire
14-12-17Update on LOXL2 Programme&Pharmaxis CollaborationRNS
08-11-17Holding(s) in CompanyRNS
27-09-17Interim results for six months ended 30 June 2017RNS
27-09-17Data update and clinical plan for COPDRNS
13-09-17Holding(s) in CompanyRNS
06-09-17Synairgen's PXS-5382A to be prepared for Phase I clinical developmentStockMarketWire
06-09-17LOXL2 Inhibitor Update.RNS
28-06-17Synairgen shareholders pass all resolutions at AGMStockMarketWire
28-06-17Result of AGMRNS
05-06-17Posting of Annual Report and Notice of AGMRNS
17-05-17Preliminary ResultsRNS
27-04-17US tax reform plans and ex-dividends push FTSE lower StockMarketWire
27-04-17Synairgen updates on AZD9412StockMarketWire
27-04-17AZD9412 UpdateRNS
27-03-17Holding(s) in CompanyRNS
13-03-17Holding(s) in CompanyRNS
10-03-17Additional Positive Data in Lung FibrosisRNS
17-01-17Holding(s) in CompanyRNS
13-10-16Holding(s) in CompanyRNS
12-10-16Synairgen updates on AZD9412StockMarketWire
12-10-16FTSE up on airlines, house builders after sluggish startStockMarketWire
12-10-16AZD9412 Clinical Trial UpdateRNS
22-09-16Broker Forecast - N+1 Singer issues a broker note on Synairgen PLCStockMarketWire
22-09-16Synairgen widens H1 pretax lossStockMarketWire
22-09-16Interim results for six months ended 30 June 2016RNS
08-09-16Notice of Interim ResultsRNS
14-06-16Result of AGMRNS
07-06-16Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?Motley Fool
17-05-16Posting of Annual Report and Notice of AGMRNS
21-04-16Holding(s) in CompanyRNS
23-03-16Synairgen options exercised StockMarketWire
23-03-16Exercise of OptionsRNS
22-03-16Broker Forecast - finnCap issues a broker note on Synairgen PLCStockMarketWire
22-03-16Positive LOXL2 resultsRNS
22-03-16Preliminary results for the year ended 31 Dec 2015RNS
03-03-16Notice of Preliminary ResultsRNS
16-11-15Adoption of FRS 101 - Reduced Disclosure FrameworkRNS
13-11-15Holding(s) in CompanyRNS
13-11-15Holding(s) in CompanyRNS

RSS feeds

  • Editorial news feed for LSE:SNG Editorial
  • Regulatory news feed for LSE:SNG Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account